Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
EnerCom Announces SM Energy as a Keynote Speaker at the 31st EnerCom Denver - The Energy Investment Conference, on August 19, 2026, in Denver, Colorado
